Close Menu

Cequent Pharmaceuticals said this week that it has received notices that the European Patent Office and the Korean Intellectual Property Office intend to grant patents covering the company's core RNAi technology.

The patent applications, entitled "Compositions for Bacterial-Mediated Gene Silencing and Methods Using the Same," relate to Cequent's so-called transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature survey finds a high level of support among scientists for former Vice President Joe Biden in the upcoming US election.

Two coronavirus vaccine trials that had been paused in the US have resumed.

The Scientist reports the physician behind Surgisphere inactivated his medical license in one state and received one in another.

In PLOS this week: analysis of link between somatic copy number and telomere length, sequencing study of individuals with gallbladder S. Typhi colonization, and more.

Oct
28
Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Nov
11
Sponsored by
Illumina

Selective breeding represents an efficient approach to increase production of aquaculture species by means of improving traits, such as rapid growth, product quality, and disease resistance.